We love sharing amazing news, and now we have even more to love! On March 17th, 2021, lanadelumab (TAKHZYRO), a subcutaneous monoclonal antibody inhibitor of plasma kallikrein, was added to the Newfoundland & Labrador Prescription Drug Program (NLPDP) benefit list; giving eligible HAE patients access to this new treatment.

Thank you to the dedicated team at Takeda Canada and to the Newfoundland & Labrador provincial government who both worked hard to give HAE patients access to this treatment in Newfoundland and Labrador.

Please CLICK HERE for the province’s Bulletin to learn more about accessing this prophylaxis (preventative) treatment in Newfoundland & Labrador.